EIF4A1

Eukaryotic initiation factor 4A-I · P60842 · EIF4A1 on Sugi Atlas →

6,358 patent compounds predicted against EIF4A1, 3,577 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Silvestrol Silvestrol (SCHEMBL732092) 1.00 19/20
Silvestrol Silvestrol (SCHEMBL5807124) 1.00 19/20
SCHEMBL12455875 SCHEMBL12455875 0.76 19/20
SCHEMBL12455880 SCHEMBL12455880 0.76 19/20
SCHEMBL10305259 SCHEMBL10305259 0.69 19/20
SCHEMBL12208427 SCHEMBL12208427 0.69 19/20
SCHEMBL12190799 SCHEMBL12190799 0.68 19/20
SCHEMBL5803471 SCHEMBL5803471 0.68 19/20
SCHEMBL2616374 SCHEMBL2616374 0.60 19/20
Aglafolin Aglafolin (SCHEMBL748617) 1.00 18/20
Rocaglamide Rocaglamide (SCHEMBL751061) 1.00 18/20
Aglafolin Aglafolin (SCHEMBL752127) 1.00 18/20
Rocaglamide Rocaglamide (SCHEMBL752144) 1.00 18/20
Rocaglamide Rocaglamide (SCHEMBL10054686) 1.00 18/20
SCHEMBL2629398 SCHEMBL2629398 0.88 18/20
SCHEMBL12182311 SCHEMBL12182311 0.87 18/20
SCHEMBL2629307 SCHEMBL2629307 0.83 18/20
SCHEMBL2629286 SCHEMBL2629286 0.74 18/20
Pannellin Pannellin (SCHEMBL2463033) 0.69 18/20
SCHEMBL12182058 SCHEMBL12182058 0.68 18/20

Clinical trials — most relevant to EIF4A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. PHASE1/PHASE2RECRUITING
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors PHASE2RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis PHASE1/PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment PHASE1COMPLETED
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors PHASE1ACTIVE_NOT_RECRUITING
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus nanCOMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EIF4A1 binder may also engage these)

ProteinNameSimilarity
P60843 1.000 P60843 →
Q3SZ54 1.000 Q3SZ54 →
Q4R8K5 1.000 Q4R8K5 →
A5A6N4 1.000 A5A6N4 →
Q5R4X1 1.000 Q5R4X1 →
Q5R5F5 1.000 Q5R5F5 →
A6M931 1.000 A6M931 →
P10630 1.000 P10630 →
Q3SZ65 1.000 Q3SZ65 →
EIF4A2 Eukaryotic initiation factor 4A-II 1.000 landscape →
Q5RKI1 1.000 Q5RKI1 →
Q5ZM36 1.000 Q5ZM36 →
Q4R4Y9 1.000 Q4R4Y9 →
EIF4A3 Eukaryotic initiation factor 4A-III 1.000 landscape →
Q9VHS8 1.000 Q9VHS8 →
P29562 1.000 P29562 →
Q3B8Q2 1.000 Q3B8Q2 →
Q2NL22 1.000 Q2NL22 →
Q5VNM3 1.000 Q5VNM3 →
P0CQ70 1.000 P0CQ70 →
B5DG42 1.000 B5DG42 →
Q4R3Q1 1.000 Q4R3Q1 →
Q4P184 1.000 Q4P184 →
Q91VC3 1.000 Q91VC3 →
Q8JFP1 1.000 Q8JFP1 →
Q5B948 1.000 Q5B948 →
B7ZTW1 1.000 B7ZTW1 →
Q02748 1.000 Q02748 →
A7EM88 0.999 A7EM88 →
A1D7N3 0.999 A1D7N3 →